GALVUS NOVARTIS PDF

Cookie policy : This site uses cookies small files stored on your computer to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Author:Vibei Tojazshura
Country:Maldives
Language:English (Spanish)
Genre:Automotive
Published (Last):18 November 2010
Pages:100
PDF File Size:6.58 Mb
ePub File Size:12.69 Mb
ISBN:786-4-36649-990-8
Downloads:25097
Price:Free* [*Free Regsitration Required]
Uploader:Kazraran



Vildagliptin is also indicated for use in combination with insulin with or without metformin when diet and exercise plus a stable dose of insulin do not provide adequate glycaemic control. Galvus is a medicine that contains the active substance vildagliptin. It is available as tablets 50 mg. The daily dose should not exceed two tablets mg. In patients with moderate or severe kidney problems, the recommended dose is 50 mg once daily.

Type-2 diabetes is a disease in which the pancreas does not make enough insulin to control the level of glucose sugar in the blood or when the body is unable to use insulin effectively. The active substance in Galvus, vildagliptin, is a dipeptidyl-peptidase-4 DPP-4 inhibitor.

These hormones are released after a meal and stimulate the pancreas to produce insulin. By increasing levels of incretin hormones in the blood, vildagliptin stimulates the pancreas to produce more insulin when blood glucose levels are high. Vildagliptin does not work when the blood glucose is low. Vildagliptin also reduces the amount of glucose made by the liver, by increasing insulin levels and decreasing the levels of the hormone glucagon.

Together, these processes reduce blood glucose levels and help to control type-2 diabetes. Galvus has been studied in eleven main studies involving a total of over 5, patients with type-2 diabetes and insufficient control of blood glucose levels. Five of these studies looked at the effects of Galvus taken alone in a total of 3, patients, comparing it with placebo a dummy treatment , metformin, rosiglitazone a thiazolidinedione or gliclazide a sulphonylurea.

Four studies compared the effects of Galvus, taken at doses of 50 or mg a day for 24 weeks, with those of placebo, when used as an add-on to existing treatment with metformin patients , pioglitazone a thiazolidinedione, patients , glimepiride a sulphonylurea, patients or insulin patients.

A further study compared Galvus with placebo as an add-on treatment in patients who were already taking metformin and glimepiride. A further study compared Galvus with placebo as an add-on treatment in patients who were already taking a stable dose of long-acting insulin. Some of the patients were also taking metformin.

In all studies, the main measure of effectiveness was the change in blood levels of a substance called glycosylated haemoglobin HbA1c , which gives an indication of how well blood glucose is controlled. Galvus used on its own was effective at reducing levels of HbA1c, but was less effective than the comparator medicines. In the study comparing Galvus with metformin, significantly better results were seen with metformin: a reduction in HbA1c of 1. When used as an add-on to existing treatment for type-2 diabetes, Galvus was more effective than placebo in reducing HbA1c levels.

With metformin and with pioglitazone, the mg daily dose was more effective than the 50 mg daily dose, with a reduction in HbA1c levels of between 0. In combination with glimepiride, both 50 mg and mg daily doses caused a reduction of around 0.

In contrast, patients adding placebo to their existing treatment showed smaller changes in HbA1c levels, ranging from a fall of 0. In combination with metformin and glimepiride, 50 mg Galvus taken twice a day reduced HbA1c levels by 1 percentage point, compared with a reduction of 0.

In the study involving patients taking insulin, adding Galvus caused a greater reduction in HbA1c levels than adding placebo, but the size of this effect was small possibly due to the fact that the study included long-term patients who were less likely to show improvement.

However, in another study involving patients taking insulin, the size of this effect was significant. Patients taking Galvus in addition to insulin, with or without metformin, had a reduction in HbA1c levels of 0. The most common side effect with Galvus seen in between 1 and 10 patients in is dizziness.

For the full list of all side effects reported with Galvus, including side effects occurring when Galvus is taken with other antidiabetes medicines, see the package leaflet. Galvus must not be used in people who are hypersensitive allergic to vildagliptin or any of the other ingredients. Because vildagliptin has been associated with liver problems, patients should have tests to check their liver function before treatment with Galvus and at regular intervals during treatment.

The CHMP noted that Galvus was effective as an add-on to metformin, a thiazolidinedione or a sulphonylurea dual therapy , a sulphonylurea and metformin triple therapy or insulin with or without metformin, and concluded that the benefits of the add-on treatment outweigh the risks. The CHMP also considered the use of Galvus on its own and concluded that it was effective in reducing blood glucose but less so than metformin. Galvus should therefore be used only in patients for whom metformin is inappropriate either because of side effects occurring with metformin or because they have a condition that makes metformin unsuitable for them.

The European Commission granted a marketing authorisation valid throughout the European Union for Galvus on 26 September For more information about treatment with Galvus, read the package leaflet also part of the EPAR or contact your doctor or pharmacist. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Available for Android and iOS devices. Subscribe to Drugs. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. We comply with the HONcode standard for trustworthy health information - verify here. Skip to Content. Drugs Galvus Print Share. What is Galvus? What is Galvus used for? Galvus is used to treat type-2 diabetes mellitus.

The medicine can only be obtained with a prescription. How is Galvus used? In adults, the recommended dose of Galvus is: one tablet in the morning and another in the evening mg per day , when used alone, with metformin, with a thiazolidinedione, with metformin plus a sulphonylurea, or with insulin with or without metformin ; one tablet in the morning 50 mg per day when taken with a sulphonylurea.

A lower dose of the sulphonylurea may also be considered to reduce the risk of hypoglycaemia low blood glucose levels. How does Galvus work? How has Galvus been studied? What benefit has Galvus shown during the studies? What is the risk associated with Galvus? Why has Galvus been approved?

Other information about Galvus The European Commission granted a marketing authorisation valid throughout the European Union for Galvus on 26 September Further information Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer. Latest Drug Information Updates. Explore Apps. About About Drugs. All rights reserved.

DMV 8016 PDF

Vildagliptin launched by Novartis for dual therapy in type 2 diabetes

The US Food and Drug Administration has sent the Swiss group an approvable letter for Galvus vildagliptin and its request for more data includes a demand for another clinical study to demonstrate the safety and efficacy of the treatment, which belongs to the new dipeptidyl peptidase DPP -4 inhibitor class, in specific patient groups with renal impairment. Last November, the firm submitted additional information to the FDA showing that reactions affecting the skin, which were seen in preclinical studies of Galvus have not been seen in human tests of the drug. This delayed the FDA's review deadline for the drug by three months and the verdict has not been positive. Novartis has given no timeline yet regarding the additional clinical trial requested by the FDA and will be hoping that Januvia has not disappeared over the horizon by the time Galvus finally gets full approval. Meantime Novartis has taken the interesting step of issuing a statement which notes that the leading proxy advisory firm ISS recommends shareholders to approve all board proposals at its annual general meeting to be held on March 6. Free news subscriptions Free RSS feeds.

ANURADHA CHECHI PDF

Novartis stock hit as FDA demands yet more Galvus data

.

CRISTOLOGIA OLEGARIO GONZALEZ DE CARDEDAL PDF

.

Related Articles